Related Experiment Video
Updated: Mar 27, 2026

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.5K
Summary
Hospitalizations for Parkinson's disease patients are 50% higher than for others. Collaborative care teams working outside the hospital may improve patient outcomes and reduce healthcare expenses.
Area of Science:
- Neurology
- Healthcare Management
- Health Economics
Background:
- Parkinson's disease (PD) patients face higher hospitalization rates (50% more) compared to the general population.
- These patients also experience significantly longer hospital stays, increasing healthcare burdens.
- Existing care models may not adequately address the complex needs of PD patients, leading to preventable admissions.
Purpose of the Study:
- To investigate the potential of interdisciplinary care teams, operating primarily outside traditional hospital settings, to enhance patient management for Parkinson's disease.
- To assess the economic impact of such collaborative care models by evaluating potential cost savings in healthcare.
- To determine if proactive, community-based interventions can reduce hospital admission rates and lengths of stay for individuals with Parkinson's disease.
Main Methods:
- Formation of specialized care teams including neurologists, nurses, physical therapists, and patient advocates.
- Implementation of remote patient monitoring and telehealth services for continuous care coordination.
- Development of personalized care plans focusing on medication management, fall prevention, and symptom control.
- Data collection on hospitalization rates, length of stay, and associated healthcare costs before and after intervention.
Main Results:
- Preliminary data suggests a reduction in hospital admission frequency among participating Parkinson's disease patients.
- Observed trends indicate a potential decrease in the average length of hospital stays for those requiring admission.
- Patient-reported outcomes show improvements in quality of life and symptom management.
- Analysis of healthcare costs is ongoing, with early indicators pointing towards potential savings.
Conclusions:
- Collaborative, community-based care models show promise in improving outcomes for Parkinson's disease patients.
- Outpatient-focused Parkinson's disease management strategies may lead to significant reductions in hospital utilization and associated costs.
- Further research and larger-scale implementation are warranted to validate these findings and optimize care delivery.
Related Concept Videos
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Drug Therapy
400
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
400
Neural Regulation
44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K
EPS and iPS Cells in Disease Research
3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K

